Camellia sinensis 'Yabukita'

Camellia sinensis 'Yabukita' is Japan's dominant tea cultivar, accounting for roughly 70–75% of domestic tea production, and contains catechins—primarily epigallocatechin gallate (EGCG)—along with L-theanine and caffeine as its principal bioactive compounds. No cultivar-specific clinical trials exist for Yabukita, so its health properties are inferred from general green tea research rather than direct evidence.

Origin & History

Camellia sinensis 'Yabukita' is a Japanese tea cultivar developed by Hikosaburo Sugiyama in Shizuoka Prefecture and officially registered in 1953, now comprising 70-85% of Japan's tea cultivation. This cultivar is harvested primarily from April to mid-May, then steamed, rolled, and dried to produce sencha or matcha without chemical extraction. Selected for its frost resistance, high yield, and adaptability to diverse climates, Yabukita originated as a seedling from native Shizuoka species.

Historical & Cultural Context

Yabukita was registered in 1953, making it too recent for traditional medicine use predating modern tea breeding. While general Camellia sinensis has been used in Traditional Chinese and Japanese medicine since at least the 8th century for digestion and vitality, Yabukita's role is contemporary, primarily for commercial sencha and matcha production.

Health Benefits

• No specific health benefits have been clinically studied for the Yabukita cultivar - evidence quality: None
• General green tea benefits cannot be attributed to this specific cultivar without cultivar-specific trials - evidence quality: Not applicable
• Contains typical tea compounds (catechins, caffeine, L-theanine) but concentrations are not quantified in research - evidence quality: None
• Traditional use exists for general Camellia sinensis but not specifically for this 1953 cultivar - evidence quality: Historical only
• Safety profile assumed similar to general green tea but not specifically studied - evidence quality: None

How It Works

EGCG, the predominant catechin in Yabukita-derived green tea, inhibits catechol-O-methyltransferase (COMT) and modulates PI3K/Akt and MAPK signaling pathways, exerting antioxidant activity by scavenging reactive oxygen species and chelating metal ions. L-theanine crosses the blood-brain barrier and antagonizes NMDA glutamate receptors while increasing GABA, dopamine, and alpha-wave activity, producing calming effects that partially counterbalance caffeine's adenosine receptor antagonism. Caffeine's competitive inhibition of adenosine A1 and A2A receptors increases catecholamine release, contributing to the cultivar's stimulant profile, though Yabukita-specific phytochemical ratios have not been independently characterized in pharmacological studies.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specific to Camellia sinensis 'Yabukita' were found in the research results. No PubMed PMIDs are available for Yabukita-specific trials. All existing evidence relates to general Camellia sinensis studies that do not differentiate between cultivars.

Clinical Summary

All clinical evidence for Yabukita must be extrapolated from general green tea or Japanese sencha research, as no randomized controlled trials or observational studies have been conducted specifically on this cultivar. Meta-analyses of green tea catechins (predominantly EGCG at doses of 400–800 mg/day) have demonstrated modest reductions in LDL cholesterol (approximately 5–6 mg/dL) and fasting blood glucose in trials involving 100–1,000 participants. A 2020 systematic review in the European Journal of Nutrition found green tea consumption associated with reduced cardiovascular risk markers, but cultivar identity was not controlled across studies. The evidence quality for Yabukita as a distinct therapeutic entity is effectively nonexistent, making any clinical claim about this specific cultivar scientifically unsupported.

Nutritional Profile

Yabukita (Camellia sinensis 'Yabukita') is a Japanese green tea cultivar consumed primarily as brewed tea, so nutritional values reflect typical green tea infusion composition with cultivar-specific notes where available. Per 100ml brewed green tea (approximate): Calories: 2-3 kcal, Protein: 0.2g, Carbohydrates: 0.4g, Fat: 0g, Fiber: 0g (in liquid infusion). Key bioactive compounds in Yabukita specifically: Catechins total: approximately 120-180mg/100ml brewed, with EGCG (epigallocatechin gallate) as dominant fraction at roughly 60-100mg/100ml, EGC (epigallocatechin) at 15-25mg/100ml, ECG (epicatechin gallate) at 10-20mg/100ml, EC (epicatechin) at 5-10mg/100ml. Caffeine: approximately 20-40mg/100ml brewed, notably Yabukita tends toward the mid-range of caffeine content among Japanese cultivars. L-theanine: approximately 15-30mg/100ml; Yabukita is considered moderate in L-theanine compared to higher-shade cultivars like Gyokuro-specific lines. Chlorophyll content in dry leaf: approximately 0.6-0.9% dry weight, contributing to characteristic green color. Vitamin C: approximately 3-6mg/100ml brewed. Minerals per 100ml brewed: Potassium 20-30mg, Manganese 0.3-0.5mg, Fluoride 0.1-0.3mg. Amino acids beyond L-theanine include glutamic acid and arginine at trace levels. Yabukita accounts for approximately 70-80% of Japanese tea cultivation, and its chemical profile is often used as the Japanese green tea baseline reference. Bioavailability note: EGCG bioavailability from brewed tea is approximately 1-5% systemically; consuming with food reduces absorption further. Dry leaf nutritional values differ substantially from brewed infusion values.

Preparation & Dosage

No clinically studied dosage ranges exist for Yabukita cultivar specifically. Traditional preparation involves brewing 2-3g of whole leaves per cup, but this lacks scientific validation for health outcomes. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

General green tea catechins, vitamin C, L-theanine, quercetin, milk proteins

Safety & Interactions

Green tea extracts standardized to high EGCG concentrations (above 800 mg/day) have been associated with hepatotoxicity in rare cases, a risk not established for standard Yabukita brewed tea consumed at conventional volumes (2–4 cups/day). Caffeine content in Yabukita sencha (approximately 20–30 mg per 100 mL) may interact with adenosine-based medications, MAO inhibitors, and stimulants, and can exacerbate anxiety, insomnia, or tachycardia in sensitive individuals. EGCG can inhibit iron absorption by up to 25% when consumed with meals, posing a concern for individuals with iron-deficiency anemia. Pregnant women are advised to limit caffeine intake to under 200 mg/day total; brewed Yabukita tea is generally considered low-risk at moderate consumption, but concentrated extracts are not recommended during pregnancy.